SAN DIEGO--(BUSINESS WIRE)--Sequenom, Inc. (NASDAQ:SQNM), a leading provider of fine mapping genotyping, methylation and gene expression analysis solutions, today announced that research conducted under the Cancer Program at the Australian-based Garvan Institute of Medical Research demonstrated the successful utilization of Sequenom’s MassARRAY® EpiTYPER™ technology for providing detailed DNA methylation analysis critical for comprehensive profiling of normal and disease DNA methylation patterns. DNA methylation is important for the functional analysis and characterization of gene targets and is widely recognized as key to understanding, and potentially treating, various forms of cancer.
